$DMAC
DiaMedica Therapeutics Inc.

2020 Q3 Form 10-Q Financial Statement

#000143774920017514 Filed on August 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.140M $1.080M $870.0K
YoY Change 9.62% 24.14% -18.69%
% of Gross Profit
Research & Development $2.158M $1.600M $1.874M
YoY Change 33.46% -14.62% 75.14%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $2.158M $1.600M $1.874M
YoY Change 33.46% -14.62% 75.14%
Operating Profit -$3.319M -$2.708M -$2.741M
YoY Change 24.73% -1.2% 48.16%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $128.0K $243.0K -$280.0K
YoY Change -43.11% -186.79% -313.74%
Pretax Income -$3.191M -$2.465M -$2.461M
YoY Change 30.99% 0.16% 43.16%
Income Tax $2.000K $9.000K $8.000K
% Of Pretax Income
Net Earnings -$3.193M -$2.474M -$2.469M
YoY Change 30.43% 0.2% 42.31%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$191.1K -$174.7K -$206.2K
COMMON SHARES
Basic Shares Outstanding 18.74M 11.96M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.60M $11.76M $10.97M
YoY Change 214.11% 7.12% 93.89%
Cash & Equivalents $9.797M $4.955M $2.974M
Short-Term Investments $20.80M $6.800M $8.000M
Other Short-Term Assets $150.0K $290.0K $200.0K
YoY Change -62.5% 45.0% 81.82%
Inventory
Prepaid Expenses
Receivables $335.0K $319.0K $1.112M
Other Receivables $320.0K $0.00
Total Short-Term Assets $31.11M $12.40M $12.28M
YoY Change 187.86% 1.0% 102.57%
LONG-TERM ASSETS
Property, Plant & Equipment $50.00K $55.00K $73.00K
YoY Change -26.47% -24.66% 4.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K
YoY Change 3.85%
Total Long-Term Assets $164.0K $182.0K $521.0K
YoY Change -29.61% -65.07% 57.88%
TOTAL ASSETS
Total Short-Term Assets $31.11M $12.40M $12.28M
Total Long-Term Assets $164.0K $182.0K $521.0K
Total Assets $31.27M $12.58M $12.80M
YoY Change 183.27% -1.69% 100.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $720.0K $552.0K $262.0K
YoY Change 130.77% 110.69% -55.59%
Accrued Expenses $658.0K $609.0K $630.0K
YoY Change -21.39% -3.33% 70.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $1.443M $1.217M $947.0K
YoY Change 19.75% 28.51% -23.63%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $20.00K
YoY Change 0.0% -50.0%
Other Long-Term Liabilities $60.00K $80.00K $130.0K
YoY Change -50.0% -38.46% -96.47%
Total Long-Term Liabilities $69.00K $92.00K $148.0K
YoY Change -48.51% -37.84% -95.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.443M $1.217M $947.0K
Total Long-Term Liabilities $69.00K $92.00K $148.0K
Total Liabilities $1.512M $1.309M $1.095M
YoY Change 12.92% 19.54% -77.74%
SHAREHOLDERS EQUITY
Retained Earnings -$64.71M -$61.52M -$51.69M
YoY Change 19.53% 19.01%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.76M $11.27M $11.70M
YoY Change
Total Liabilities & Shareholders Equity $31.27M $12.58M $12.80M
YoY Change 183.27% -1.69% 100.27%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$3.193M -$2.474M -$2.469M
YoY Change 30.43% 0.2% 42.31%
Depreciation, Depletion And Amortization $10.00K $0.00 $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$2.350M -$840.0K -$2.880M
YoY Change 91.06% -70.83% 182.35%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$14.00M $2.500M $3.010M
YoY Change -566.67% -16.94%
Cash From Investing Activities -$14.00M $2.500M $3.010M
YoY Change -566.67% -16.94% -30200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $23.00M $23.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.18M 0.000 70.00K
YoY Change -100.0% 40.0%
NET CHANGE
Cash From Operating Activities -2.350M -840.0K -2.880M
Cash From Investing Activities -14.00M 2.500M 3.010M
Cash From Financing Activities 21.18M 0.000 70.00K
Net Change In Cash 4.830M 1.660M 200.0K
YoY Change 172.88% 730.0% -120.41%
FREE CASH FLOW
Cash From Operating Activities -$2.350M -$840.0K -$2.880M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$2.350M -$840.0K -$2.880M
YoY Change 91.06% -70.83% 185.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Type
DocumentType
10-Q
dei Entity Shell Company
EntityShellCompany
false
dei Trading Symbol
TradingSymbol
dmac
dei Security12b Title
Security12bTitle
Voting common shares, no par value per share
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Registrant Name
EntityRegistrantName
DiaMedica Therapeutics Inc.
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18739074
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q2 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
188000
CY2019Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
172000
CY2020Q2 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
23000
CY2019Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
52000
CY2020Q2 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
65000
CY2019Q2 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
226000
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
180000
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
400000
CY2020Q2 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
166000
CY2019Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
433000
dmac Noncash Lease Expense
NoncashLeaseExpense
26000
dmac Noncash Lease Expense
NoncashLeaseExpense
24000
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000
CY2020Q3 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
21100000
CY2020Q2 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
264000
CY2019Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
793000
CY2020Q2 dmac Working Capital
WorkingCapital
11200000
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
609000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1076000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
552000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
182000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
319000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
823000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
609000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1076000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-221000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
29000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2020Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
72759000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64232000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
436000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
182000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
829000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
312000
CY2020Q2 us-gaap Assets
Assets
12581000
CY2019Q4 us-gaap Assets
Assets
9053000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
12399000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
8836000
CY2020Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
182000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
217000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4955000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3883000
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
5000000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3883000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16823000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4955000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2974000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1072000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13849000
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2819776
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14139074
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12006874
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14139074
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12006874
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2487000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2461000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4872000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5710000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <div style="display: inline; font-style: italic; font: inherit;">two</div> financial institutions. These balances generally exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses in such accounts and believes it is <div style="display: inline; font-style: italic; font: inherit;">not</div> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</div></div></div></div></div>
CY2020Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
46000
CY2019Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
88000
us-gaap Depreciation
Depreciation
11000
us-gaap Depreciation
Depreciation
11000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
232000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
419000
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
10000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
13000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1079000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
867000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
370000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2102000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1681000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2465000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2461000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4881000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5704000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17000
CY2020Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
37000
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
13000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12581000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9053000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1217000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1318000
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
92000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
118000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-504000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
332000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-494000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-196000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-42000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
188000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-171000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
23000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
53000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
147000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
68000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
46000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
33000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15000
CY2020Q2 us-gaap Marketable Securities
MarketableSecurities
6800000
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
6844000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3995000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7695000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2801000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7916000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3822000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6005000
us-gaap Net Income Loss
NetIncomeLoss
-4899000
us-gaap Net Income Loss
NetIncomeLoss
-5721000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2474000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2469000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-243000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-231000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-458000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2708000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2741000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5112000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6162000
us-gaap Operating Lease Cost
OperatingLeaseCost
32000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
132000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
127000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
178000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58000
CY2020Q2 us-gaap Other Receivables
OtherReceivables
18000
CY2019Q4 us-gaap Other Receivables
OtherReceivables
17000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-12000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8799000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10928000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
235000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7682000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
6000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
3000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
17025000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
11702000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
109000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
107000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1629000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1874000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3010000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4481000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61516000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56617000
us-gaap Share Based Compensation
ShareBasedCompensation
829000
us-gaap Share Based Compensation
ShareBasedCompensation
312000
CY2020Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
785972
CY2020Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1413988
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y109D
CY2020Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.19
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y36D
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
829000
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
312000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7682000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
11272000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000
us-gaap Variable Lease Cost
VariableLeaseCost
26000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14139074
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11979401
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13623400
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11968200

Files In Submission

Name View Source Status
0001437749-20-017514-index-headers.html Edgar Link pending
0001437749-20-017514-index.html Edgar Link pending
0001437749-20-017514.txt Edgar Link pending
0001437749-20-017514-xbrl.zip Edgar Link pending
chart01.jpg Edgar Link pending
dmac-20200630.xml Edgar Link completed
dmac-20200630.xsd Edgar Link pending
dmac-20200630_cal.xml Edgar Link unprocessable
dmac-20200630_def.xml Edgar Link unprocessable
dmac-20200630_lab.xml Edgar Link unprocessable
dmac-20200630_pre.xml Edgar Link unprocessable
dmtp20200630_10q.htm Edgar Link pending
ex_197539.htm Edgar Link pending
ex_197540.htm Edgar Link pending
ex_197541.htm Edgar Link pending
ex_197542.htm Edgar Link pending
ex_198797.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending